EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an “Old” Genetic Myocardial Disease

Chiara Calore, Mario Mangia iD, Cristina Basso iD, Domenico Corrado, Gaetano Thiene iD

Genes · 10.01.2025 · 16 (1) · 74

DOI: 10.3390/genes16010074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 10.01.2025. Verfasst von Chiara Calore und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, 35128 Padova, Italy. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Registry of Cardio-Cerebro-Vascular Pathology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since its first pathological description over 65 years ago, hypertrophic cardiomyopathy (HCM), with a worldwide prevalence of 1:500, has emerged as the most common genetically determined cardiac disease. Diagnostic work-up has dramatically improved over the last decades, from clinical suspicion and abnormal electrocardiographic findings to hemodynamic studies, echocardiography, contrast-enhanced cardiac magnetic resonance, and genetic testing. The implementation of screening programs and the use of implantable cardioverter defibrillators (ICDs) for high-risk individuals have notably reduced arrhythmic sudden deaths, altering the disease’s mortality profile. Therapeutic breakthroughs, including surgical myectomy, alcohol septal ablation, and the novel introduction of “myosin inhibitors”, have revolutionized symptom management and reduced progression to advanced heart failure (HF) and death. Despite this progress, refractory HF—both with preserved and reduced systolic function—has become the predominant cause of HCM-related mortality. While most patients with HCM experience a favorable clinical course with low morbidity and mortality, timely identification and targeted treatment of high-risk subgroups progressing toward progressive HF remain a pressing challenge, even for expert clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansHeart FailureDefibrillators, Implantable

Stichwörter der Autor:innen

geneticsheart failurehypertrophic cardiomyopathynew drugssudden cardiac deathsurgerytransplantationtreatment

Autor:innen und Institutionen

  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, 35128 Padova, Italy.

ORCID-Profile: Mario Mangia, Cristina Basso, Gaetano Thiene

Förderung

  • Registry of Cardio-Cerebro-Vascular Pathology

Zitieren

APA

Calore, C., Mangia, M., Basso, C., Corrado, D., & Thiene, G. (2025). Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an “Old” Genetic Myocardial Disease. Genes, 16(1), 74. https://doi.org/10.3390/genes16010074

Vancouver

Calore C, Mangia M, Basso C, Corrado D, Thiene G. Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an “Old” Genetic Myocardial Disease. Genes. 2025;16(1):74. doi:10.3390/genes16010074

BibTeX
@article{Calore2025,
  author = {Calore, Chiara and Mangia, Mario and Basso, Cristina and Corrado, Domenico and Thiene, Gaetano},
  title = {Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an “Old” Genetic Myocardial Disease},
  journal = {Genes},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {74},
  doi = {10.3390/genes16010074}
}
Kostenlos starten →